The stock has been in a pronounced downtrend over the last six months, declining 8.06% from October 2025 to the current price of $217.49. This underperformance is more severe than the broader market, as indicated by a -5.24 relative strength over the same period. Short-term performance has been weak, with the stock down 6.29% over the past month and 4.81% over the past three months, both periods showing negative relative strength versus the S&P 500. The current price of $217.49 sits significantly closer to its 52-week low of $164.39 than its high of $244.81, trading at approximately 73% of the range's width from the low. The price data shows a sharp decline in mid-March 2026, falling from around $227 to a low near $205 before a modest recovery.

Revenue growth has been positive, with Q4 2025 revenue of $16.62 billion representing a 10.04% year-over-year increase. Profitability has improved markedly from the prior year's Q4 net loss, with the latest quarter showing a net income of $1.82 billion and a net margin of 10.93%. However, quarterly profitability has been volatile, as seen in the significant drop in Q3 2025. The company's financial health shows a high debt burden with a negative debt-to-equity ratio of -21.12, indicating significant liabilities relative to shareholder equity. Cash flow generation remains strong, with trailing twelve-month free cash flow of $18.70 billion, providing ample coverage for its dividend. Operational efficiency metrics are mixed, with a positive Return on Assets (ROA) of 9.81% but a deeply negative Return on Equity (ROE) of -129.24%, largely distorted by the negative equity position.